[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201906430RA - Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same - Google Patents

Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same

Info

Publication number
SG11201906430RA
SG11201906430RA SG11201906430RA SG11201906430RA SG11201906430RA SG 11201906430R A SG11201906430R A SG 11201906430RA SG 11201906430R A SG11201906430R A SG 11201906430RA SG 11201906430R A SG11201906430R A SG 11201906430RA SG 11201906430R A SG11201906430R A SG 11201906430RA
Authority
SG
Singapore
Prior art keywords
international
dialkylaminomethyl
benzamides
piperidin
pct
Prior art date
Application number
SG11201906430RA
Inventor
Brett Tounge
Shariff Bayoumy
Lawrence Kuo
Scott Dax
Original Assignee
Mebias Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mebias Discovery Inc filed Critical Mebias Discovery Inc
Publication of SG11201906430RA publication Critical patent/SG11201906430RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/06—Preparation of indole from coal-tar
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PUBLISHEDUNDER THE PATENT COOPERATION TREATY (PCT) omit VIII °nolo ioo Eno oimIE (10) International Publication Number WO 2018/136546 Al WIPO I PCT (12) INTERNATIONAL APPLICATION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) (51) International Patent Classification: A61K 31/445 (2006.01) C07D 401/04 (2006.01) (21) International Application Number: PCT/US2018/014090 (22) International Filing Date: 17 January 2018 (17.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/447,197 17 January 2017 (17.01.2017) US 62/599,834 18 December 2017 (18.12.2017) US (71) Applicant: MEBIAS DISCOVERY LLC [US/US]; 3025 Market Street, Suite 140, Philadelphia, PA 19104 (US). (72) Inventors: TOUNGE, Brett, A.; 1014 Blue Rock Lane, Blue Bell, PA 19422 (US). BAYOUMY, Shariff; 227 South 10th Street, North Wales, PA 19454 (US). KUO, Lawrence, C.; 701 Penrith Place, Gwynedd Valley, PA 19437 (US). DAX, Scott, L.; 3 Quail Drive, Landenberg, PA 19350 (US). (74) Agent: SILVA, Domingos, J. et al.; Saul Ewing Arnstein & Lehr LLP, 1500 Market Street, 38th Floor, Philadelphia, PA 19102 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 O \" (57) : The invention relates to certain substituted 3-dialkylaminomethyl-piperidin-4-yl- benzamides, and compositions com- C prising the same, which in certain embodiments are useful for treating and/or preventing pain in a subject in need thereof. (54) Title: SUBSTITUTED 3-DIALKYLAMINOMETHYL-PIPERIDIN-4-YL-BENZAMIDES AND METHODS OF MAKING AND USING SAME
SG11201906430RA 2017-01-17 2018-01-17 Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same SG11201906430RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447197P 2017-01-17 2017-01-17
US201762599834P 2017-12-18 2017-12-18
PCT/US2018/014090 WO2018136546A1 (en) 2017-01-17 2018-01-17 Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same

Publications (1)

Publication Number Publication Date
SG11201906430RA true SG11201906430RA (en) 2019-08-27

Family

ID=62909071

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906430RA SG11201906430RA (en) 2017-01-17 2018-01-17 Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same

Country Status (9)

Country Link
US (3) US10836728B2 (en)
EP (1) EP3570838B1 (en)
JP (1) JP7149961B2 (en)
KR (1) KR102603671B1 (en)
CN (2) CN110392571B (en)
AU (1) AU2018211057B2 (en)
CA (1) CA3050515A1 (en)
SG (1) SG11201906430RA (en)
WO (1) WO2018136546A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007422QA (en) 2018-02-05 2020-09-29 Alkermes Inc Compounds for the treatment of pain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202345A (en) 1987-08-19 1993-04-13 Shionogi & Co., Ltd. Carbamoylpyrrolidone derivatives and drugs for senile dementia
SE9802208D0 (en) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
HN1999000149A (en) 1998-09-09 2000-01-12 Pfizer Prod Inc DERIVATIVES OF 4,4-BIARILPIPERIDINA
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB0030305D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
DE10112198A1 (en) * 2001-03-14 2002-09-19 Gruenenthal Gmbh Substituted dimethyl- [1- (1-phenylcyclohexyl) piperidin-3-ylmethyl] amines
US7368444B2 (en) 2002-02-14 2008-05-06 Ono Pharmaceutical Co., Ltd. N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient
EP1499898A2 (en) 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulation of tnf-alpha
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
CA2566601C (en) 2004-05-14 2013-04-09 Janssen Pharmaceutica N.V. Carboxamido opioid compounds
US20110237622A1 (en) * 2008-12-10 2011-09-29 Merck Frosst Canada Ltd. Renin inhibitors
WO2015091939A1 (en) 2013-12-20 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Piperidine derivatives having multimodal activity against pain
CN105646332B (en) * 2014-11-09 2018-05-25 复旦大学 Aminomethylpiperidine analog derivative and preparation method thereof and medicinal usage

Also Published As

Publication number Publication date
CN116751156A (en) 2023-09-15
EP3570838A1 (en) 2019-11-27
US20210101868A1 (en) 2021-04-08
EP3570838B1 (en) 2024-06-05
KR102603671B1 (en) 2023-11-17
US10836728B2 (en) 2020-11-17
JP7149961B2 (en) 2022-10-07
US11319290B2 (en) 2022-05-03
AU2018211057A1 (en) 2019-08-08
CN110392571B (en) 2023-07-04
US20240043387A1 (en) 2024-02-08
EP3570838A4 (en) 2021-01-27
AU2018211057B2 (en) 2021-12-23
KR20190104195A (en) 2019-09-06
CA3050515A1 (en) 2018-07-26
US20190337901A1 (en) 2019-11-07
WO2018136546A1 (en) 2018-07-26
CN110392571A (en) 2019-10-29
JP2020504187A (en) 2020-02-06

Similar Documents

Publication Publication Date Title
SG11201909949XA (en) Targeted immunotolerance
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201809064QA (en) Chimeric neurotoxins
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201908567UA (en) Modified cyclic dinucleotide compounds
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201900596XA (en) Cannabis composition
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201407747QA (en) A method and apparatus for facilitating the management of health and security
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201901374WA (en) Antibiotic compounds
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201908472VA (en) Compositions and methods for activating nk cells
SG11201805001UA (en) Method of treating influenza a
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia